Thomas Rexer
CEO
E
eversyn
9/10Traction
This company produces premium-grade glycan building blocks and enzymes using cell-free enzymatic synthesis. They provide scalable access to high-value activated sugars and complex HMOs for R&D and industrial applications. Their offerings support advancements in biopharmaceuticals, ADCs, and next-generation nutrition products.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$500KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BmpNo round attributed
- bmp.com (opens in a new tab)investor website
Funding rounds are not available yet.
Founders
Product
Problem
High-value glycans, such as nucleotide sugars and human milk oligosaccharides (HMOs), are crucial for human health research and biopharmaceutical development, but their limited availability and high production costs hinder scientific advancement and the creation of new therapies. Researchers and industry professionals face challenges in accessing these essential molecules at scales necessary for both R&D and industrial applications.
Solution
Eversyn utilizes a cell-free biocatalytic platform to produce nucleotide sugars and human milk oligosaccharides (HMOs) at significantly reduced costs compared to traditional cell-based methods. This technology enables the affordable production of activated sugars and glycoengineering enzymes, providing researchers with essential building blocks for glycans. By offering these previously scarce molecules at accessible prices, Eversyn facilitates advancements in nutrition, biopharma, and the development of next-generation biopharmaceuticals with tailored glycoforms. The company's approach allows for precise control over protein glycosylation and glycan engineering, improving the efficacy and safety of novel therapeutics.
Target Audience
Eversyn's primary customers are B2B professionals in the research and development sectors of the nutrition and biopharmaceutical industries, including researchers working with human milk oligosaccharides, specialty carbohydrates, and therapeutic proteins.
Features
- Proprietary biocatalytic cascades for efficient production of nucleotide sugars and HMOs
- Affordable activated sugars, including GDP-fucose, CMP-N-Acetylneuraminic Acid, UDP-GlcNAc, and UDP-galactose, available in various sizes
- Glycoengineering tools, including alpha-1,6-fucosidase, alpha-2,6-sialyltransferase, and alpha-1,3-galactosyltransferase
- Enzymes for in vitro glycoengineering, offered in both liquid and solid forms with varying unit sizes
- Capability to tailor glycoforms to customer specifications through biocatalysis and glycoanalytics expertise
- Stringent quality testing by third parties to ensure product reliability